biostudies-literatureUnknown15Ma J<h4>Background</h4>We aimed to report our clinical experience with the use of ²²⁵Ac-PSMA-617 in the treatment of mCRPC patients.<h4>Methods</h4>A retrospective analysis was conducted on 29 metastatic castration-resistant prostate cancer (mCRPC) patients treated with ²²⁵Ac-PSMA-617. Patients underwent treatment at 8-week intervals and discontinued treatment upon disease progression or the occurrence of intolerable adverse effects. We acquired ⁶⁸Ga-PSMA-11 PET/CT images and laboratory test outcomes of patients at baseline and 8 weeks following each treatment. Short-term efficacy was evaluated through the biochemical response of serum prostate-specific antigen (PSA) and molecular tumor response criteria. A follow-up was conducted to assess the long-term effectFrontiers in oncology1516860https://www.ebi.ac.uk/biostudies/studies/S-EPMC11906306biostudies-literatureThe efficacy and safety of &lt;sup&gt;225&lt;/sup&gt;Ac-PSMA-617 in metastatic castration-resistant prostate cancer.PMC11906306Yangqing JZhang YMa JZhang CWang JLiu GfalseThe efficacy and safety of &lt;sup&gt;225&lt;/sup&gt;Ac-PSMA-617 in metastatic castration-resistant prostate cancer.<h4>Background</h4>We aimed to report our clinical experience with the use of ²²⁵Ac-PSMA-617 in the treatment of mCRPC patients.<h4>Methods</h4>A retrospective analysis was conducted on 29 metastatic castration-resistant prostate cancer (mCRPC) patients treated with ²²⁵Ac-PSMA-617. Patients underwent treatment at 8-week intervals and discontinued treatment upon disease progression or the occurrence of intolerable adverse effects. We acquired ⁶⁸Ga-PSMA-11 PET/CT images and laboratory test outcomes of patients at baseline and 8 weeks following each treatment. Short-term efficacy was evaluated through the biochemical response of serum prostate-specific antigen (PSA) and molecular tumor response criteria. A follow-up was conducted to assess the long-term effect2025-01-01T00:00:00Z20252025-04-04T14:48:08.716Z2025-04-04T14:48:08.716ZS-EPMC119063064009400410.3389/fonc.2025.1516860